Q4 highlights: NUVA expects U.S. Spinal Hardware revenue increased ~8%; U.S. Surgical Support revenue increased ~3% and International revenue increased ~14% on a reported and constant currency basis.
#JPM20
Monday, January 13, 2020
ViewRay announces preliminary Q4 results
Total Q4 revenue of ~$17M vs. consensus of $18.26M and $21M year ago.
Received four new orders for MRIdian systems totaling ~$21M in the quarter, compared to eight new orders totaling ~$49M in 4Q18.
FY2019 revenue of ~$88M vs. consensus of $89.83M and $81M year ago.
Total backlog was ~$227M and Cash and cash equivalents were ~$227M as of December 31, 2019.
Cash burn in the quarter was ~$3M.
Chief Commercial Officer Jim Alecxih will be leaving the company effective January 17, 2020.
#JPM20
AxoGen reports preliminary Q4 and FY 2019 revenue outlook
Q4 and FY revenue is expected to be at least $28.1M and $106.6M, respectively.
Ended Q4 with 109 direct sales representatives.
Increased active accounts in Q4 to 797, up 12% from 712 in Q4 2018.
FY 2020 revenue is expected in the range of approx. $124M to $128M and number of direct sales representatives will increase to approx. 126 to 131.
Gross margin to remain above 80%.
The Company will report full, audited results for Q4 and FY 2019 on February 24, 2020.
#JPM20
GenMark Diagnostics reports 2019 operational and financial outlook
GenMark Diagnostics (GNMK -3.7%) provides preliminary operational and financial results for FY 2019.
Total revenue for FY 2019 and Q4 is expected to be ~$88M, +24% Y/Y and ~$27M, respectively.
ePlex revenue for FY 2019 and Q4 of ~$60M, +59% Y/Y and ~$19M, respectively.
Gross margin is expected to be between 33% and 34% for Q4 and between 32% and 33% for FY 219.
The Company placed 48 new ePlex analyzers in Q4, for a net increase of 38 to the installed base finishing the year with 527 ePlex analyzers placed worldwide.
ePlex installed base grew 49% Y/Y.
Q4 annuity was ~$148 thousand per analyzer.
The Company expects to issue full 2019 financial results and 2020 guidance in late February.
Guardant Health teams up with Amgen to develop CDx test
Guardant Health (GH -2.2%) will collaborate with Amgen (AMGN -1%) on developing a blood-based companion diagnostic (CDx) test for candidate AMG 510.
GH will pursue regulatory approvals in the U.S., Europe and Japan for its Guardant360 CDx for this use in metastatic non-small cell lung cancer.
Retrophin provides corporate update and 2020 outlook
The Company expects net product sales for Q4 and FY 2019 to be ~$47M and ~$175M, respectively.
Top-line efficacy data from Phase 3 DUPLEX Study is expected in H1 2021.
Top-line data from Phase 3 PROTECT Study is expected in H1 2022.
In 2020, the Company expects continued organic growth of its rare nephrology and hepatology products.
RTRX expects to announce complete full year 2019 financial results in late February.
Medtronic’s InterStim Micro CE Mark’d
Subscribe to:
Posts (Atom)